Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users

Contraception

Volumn 73, Issue 6, 2006, Pages 584-587

  Nathirojanakun, Prapoj ^a   Taneepanichskul, Surasak ^a   Sappakitkumjorn, Nattiporn ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Depot medroxyprogesterone acetate (DMPA); Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MEDROXYPROGESTERONE ACETATE; PLACEBO; VALDECOXIB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MEDROXYPROGESTERONE 17-ACETATE; MENORRHAGIA; MENSTRUATION DISTURBANCES; MIDDLE AGED; SULFONAMIDES;

EID: 33646757553     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2005.09.013     Document Type: Article

References (18)

1. Taneepanichskul S., Reinprayoon D., and Phaosavadi S. DMPA use above the age of 35 in Thai women. Contraception 61 (2000) 281-282
2. Chotnopparatpattara P., and Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception 62 (2000) 137-140
3. Vincent A.J., Zhang J., Ostor A., et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?. Hum Reprod 17 (2002) 1189-1198
4. Lockwood C.J., Runic R., Wan L., Krikun G., Demopolous R., and Schatz F. The role of tissue factor in regulating endometrium haemostasis: implications for progestin-only contraception. Hum Reprod 15 Suppl 3 (2000) 144-151
5. Subakir S.B., Abdul Maduid O., Sabariah S., and Affandi B. Oxidative stress, vitamin E and progestin breakthrough bleeding. Hum Reprod 15 Suppl 3 (2000) 18-23
6. Frasor I.S., and Hickey M. Endometrial vascular change and bleeding disturbance with long-acting progestin. Steroids 65 (2000) 665-670
7. Mitchell M.D. Reproductive roles of eicosamoids. In: Adashi E.Y., Rock J.A., and Rosenwaks Z. (Eds). Reproductive endocrinology, surgery and technology (1996), Lippincott-Raven, Philadelphia 841-858
8. Speroff L., and Fritz M.A. Long-acting methods of contraception. In: Speroff L., and Fritz M.A. (Eds). Clinical gynecologic endocrinology and infertility. 7th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 949-969
9. Bonnar J., and Sheppard B.L. Treatment of menorrhagia during menstruation: randomised control trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313 (1996) 579-582
10. Van Eijkeren M.A., Christiaens G.C., Geuze H.J., Haspels A.A., and Sixma J.J. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 166 (1992) 1419-1428
11. Chamberlain G., Freeman R., Price F., Kennedy A., Green D., and Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 98 (1991) 707-711
12. Grover V., Usha R., Gupta U., and Kalra S. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania Obstet Gynecol 16 (1990) 255-259
13. FitzGerald G.A. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89 Suppl 6A (2002) 26-32
14. Fraser I.S. Prostaglandin inhibitors in gynaecology. Aust N Z J Obstet Gynaecol 25 (1985) 114-117
15. Mishell Jr. D.R. Abnormal uterine bleeding: ovulatory and anovulatory dysfunctional uterine bleeding, management of acute and chronic excessive bleeding. In: Mishell D.R., Stenchever M.A., Droegemueller W., and Herbst A.L. (Eds). Comprehensive gynecology. 3rd ed. (1997), C.V. Mosby, New Jersey 1025-1042
16. Catella-Lawson F., and Crofford L.J. Cyclooxygenase inhibition and thrombogenicity. Am J Med 110 Suppl 3A (2001) 28-32
17. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96 (1999) 272-277
18. Catella-Lawson F., McAdam B., Morrison B.W., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289 (1999) 735-741